Your browser doesn't support javascript.
loading
The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen, R A W; Keymeulen, K B M I; Kooreman, L F S; van Kuijk, S M J; Siesling, S; Smidt, M L; van Nijnatten, T J A.
Afiliación
  • Ploumen RAW; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands. Electronic address: r.ploumen@maastrichtuniversity.nl.
  • Keymeulen KBMI; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: k.keymeulen@mumc.nl.
  • Kooreman LFS; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands; Department of Pathology, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: loes.kooreman@mumc.nl.
  • van Kuijk SMJ; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: sander.van.kuijk@mumc.nl.
  • Siesling S; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, 7522 NH, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, 3511 DT, Utrecht, the Netherlands. Electronic address: s.siesling@iknl.nl.
  • Smidt ML; Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands. Electronic address: m.smidt@mumc.nl.
  • van Nijnatten TJA; Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: thiemo.nijnatten@mumc.nl.
Eur J Surg Oncol ; 48(1): 60-66, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34756527
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Ductal de Mama / Carcinoma Intraductal no Infiltrante / Terapia Neoadyuvante / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Ductal de Mama / Carcinoma Intraductal no Infiltrante / Terapia Neoadyuvante / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article